Suscribirse

Medication performance measures and mortality following acute coronary syndromes - 21/08/11

Doi : 10.1016/j.amjmed.2005.01.070 
Christopher B. Granger, MD a, , Philippe Gabriel Steg, MD b, Eric Peterson, MD, MPH a, José López-Sendón, MD c, Frans Van de Werf, MD, PhD d, Eva Kline-Rogers, RN f, Jeanna Allegrone e, Omar H. Dabbous, MD, MPH e, Werner Klein, MD g, Keith A.A. Fox, MB, ChB h, Kim A. Eagle, MD f

GRACE Investigators

  A complete list of investigators and institutions can be found in the Appendix.

a Duke University Medical Center, Durham, NC 
b Hôpital Bichat, Paris, France 
c Hospital General U. Gregorio Maranon, Madrid, Spain 
d Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium 
e University of Massachusetts Medical School, Worcester 
f University of Michigan Health System, Ann Arbor 
g Department of Internal Medicine, Krankenhaus der Barmherzigen Bruder, Teaching Hospital of the Karl Franzens University Graz, Graz, Austria 
h The University and The Royal Infirmary of Edinburgh, Edinburgh, Scotland. 

Requests for reprints should be addressed to Christopher B. Granger, MD, Duke Clinical Research Institute, 2400 Pratt Street, Room 0311 Terrace Level, Durham, NC 27705.

Abstract

Purpose

To identify patient and health care factors which are related to the use of medical treatments that comprise quality measures and to assess the relation of these measures with mortality.

Methods

The study sample consisted of 20 140 patients with acute coronary syndromes from the international GRACE registry. Multivariable logistic regression modeling was used to determine predictors of quality performance. Quality indicators were use of aspirin and beta-blockers within 24 hours and at hospital discharge, use of angiotensin-converting enzyme (ACE) inhibitors at discharge, and in-hospital mortality.

Results

Use of medications in eligible patients at discharge ranged from 73% for ACE inhibitors to 93% for aspirin. High-risk features (eg, heart failure, older age) were related to failure to use aspirin and beta-blockers. Being at a teaching hospital and care by a cardiologist were associated with better use of aspirin and beta-blockers. Coronary artery bypass surgery was associated with failure to use ACE inhibitors and aspirin. When hospitals were divided into quartiles of quality performance, adjusted in-hospital mortality was 4.1% in the top versus 5.6% in the bottom quartile, representing a 27% (95% confidence interval: 11% to 42%) lower relative mortality.

Conclusion

Identification of factors associated with failure to use proven treatments, including high-risk groups that would derive particular benefit from effective therapies, provides an opportunity to focus quality improvement interventions. The association of lower hospital mortality with better use of selected medical treatments supports their measurement to improve quality of care.

El texto completo de este artículo está disponible en PDF.

Keywords : Acute coronary syndromes, Quality, Mortality


Esquema


 GRACE is supported by an unrestricted educational grant from Aventis Pharma (Bridgewater, NJ).


© 2005  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 118 - N° 8

P. 858-865 - août 2005 Regresar al número
Artículo precedente Artículo precedente
  • Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer
  • Steven B. Zeliadt, Ruth D. Etzioni, David F. Penson, Ian M. Thompson, Scott D. Ramsey
| Artículo siguiente Artículo siguiente
  • A simple clinical score accurately predicts outcome in a community-based population undergoing stress testing
  • Todd D. Miller, Veronique L. Roger, David O. Hodge, Raymond J. Gibbons

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.